Gene expression of PMP22 is an independent prognostic factor for disease-free and overall survival in breast cancer patients

BMC Cancer

Research Article

Margaretha Rudas¹  Gerda Hofstetter²  Nicole Concin²  Andrea Wolf³  Ingrid Schiebel³  Dan Tong³  Christian F Singer³  Robert Zeillinger⁴  Dietmar Pils⁵  Georg Heinze⁶ 

[1] Clinic Institute of Pathology, Medical University of Vienna, Währinger Gürtel 18-20, 1090, Vienna, Austria;Department of Gynaecology and Obstetrics, Innsbruck Medical University, Christoph-Probst-Platz, Innrain 52, 6020, Innsbruck, Austria;Department of Obstetrics and Gynaecology, Medical University of Vienna, EBO 5Q, AKH, Währinger Gürtel 18-20, 1090, Vienna, Austria;Department of Obstetrics and Gynaecology, Medical University of Vienna, EBO 5Q, AKH, Währinger Gürtel 18-20, 1090, Vienna, Austria;Ludwig-Boltzmann Cluster Translational Oncology; EBO 5Q, AKH, Waehringer Guertel 18-20, 1090, Vienna, Austria;Ludwig-Boltzmann Cluster Translational Oncology; EBO 5Q, AKH, Waehringer Guertel 18-20, 1090, Vienna, Austria;Section of Clinical Biometrics, Center for Medical Statistics, Informatics and Intelligent Systems, Medical University of Vienna, Spitalgasse 23, 1090, Vienna, Austria;

关键词: Breast Cancer;    Overall Survival;    Estrogen Receptor;    Breast Cancer Patient;    Estrogen Receptor Status;   

DOI  :  10.1186/1471-2407-10-682

 received in 2010-04-09, accepted in 2010-12-15,  发布年份 2010

来源: Springer

【 摘 要 】

BackgroundGene expression of peripheral myelin protein 22 (PMP22) and the epithelial membrane proteins (EMPs) was found to be differentially expressed in invasive and non-invasive breast cell lines in a previous study. We want to evaluate the prognostic impact of the expression of these genes on breast cancer.MethodsIn a retrospective multicenter study, gene expression of PMP22 and the EMPs was measured in 249 primary breast tumors by real-time PCR. Results were statistically analyzed together with clinical data.ResultsIn univariable Cox regression analyses PMP22 and the EMPs were not associated with disease-free survival or tumor-related mortality. However, multivariable Cox regression revealed that patients with higher than median PMP22 gene expression have a 3.47 times higher risk to die of cancer compared to patients with equal values on clinical covariables but lower PMP22 expression. They also have a 1.77 times higher risk to relapse than those with lower PMP22 expression. The proportion of explained variation in overall survival due to PMP22 gene expression was 6.5% and thus PMP22 contributes equally to prognosis of overall survival as nodal status and estrogen receptor status. Cross validation demonstrates that 5-years survival rates can be refined by incorporating PMP22 into the prediction model.ConclusionsPMP22 gene expression is a novel independent prognostic factor for disease-free survival and overall survival for breast cancer patients. Including it into a model with established prognostic factors will increase the accuracy of prognosis.

【 授权许可】

CC BY   
© Tong et al; licensee BioMed Central Ltd. 2010. This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.